These look cheap to me
- Markets
- Stocks
- Novo-Nordisk ADR repsg 1 B
- Forum Discussion

Novo-Nordisk ADR repsg 1 B
Price
Discussion about NVO
Posts
59Portfolio
Dear Getquin Community,
I've been here for about a year and have already learned a lot...but now I'm thinking about changing positions.
as they no longer quite fit my strategy.
But I'm having doubts, as some positions are quite negative.
What do you think?
🚀 New miracle cure? Novo Nordisk with impressive weight loss results! 💊⚖️
🏢 Novo Nordisk $NOVO B (+2.06%)
$NVO (+1.85%) presents new study results on amycretin presented
⚗️ Up to 24% weight loss in overweight and obese adults
💉 Administration:
- Weekly injections:
- 20 mg ➔ 22 % weight loss (after 36 weeks)
- 60 mg ➔ 24.3 % weight loss
- Daily tablet:
- 50 mg ➔ 10.4 % weight loss (after 12 weeks)
- 100 mg ➔ 13.1 % weight loss
🔬 Dual mode of action:
- GLP-1 mimic (like Wegovy)
- Amylin receptors for additional hunger management
🤢 Side effects: mainly gastrointestinal complaints, comparable to other weight loss medications
📅 Phase 3 trials to start in 2026, followed by possible approval
🩺 Experts emphasize: Cardiovascular risks and comorbidities remain important
🔬 Further studies needed for direct comparison with existing drugs such as Ozempic
Source:
https://de.tradingview.com/news/reuters.com,2025:newsml_L8N3SN1L8:0/

New strategy
Hello everyone,
I have been thinking and considering for some time now. After my portfolio presentation, I looked again and thought about how and which strategy I want to pursue exactly.
Here is my first approach for the new strategy:
📊 60% Core - ETF savings plans
$IWDA (+0.48%) -> 25 %
$VHYL (+0.63%) -> 15 %
$DGIT (-0.02%) -> 20 %
🧭 30 % satellite savings plan
$MSFT (-0.33%) -> 10 %
$KO (+0.24%) -> 10%
$PEP (+1.72%) -> 5%
$ASML (+1.43%) ->5 %
🎯 10% opportunity satellites - savings plan
$NVO (+1.85%) -> 5%
$BTC (+0.57%) -> 2,5 %
$ARCA (-6.49%) -> 2,5%
What do you think of this setup? I would let the current shares continue to run and sell them at a profit when the opportunity arises.
This would be my second attempt to build a proper portfolio. My budget is not that big but I am making the best of it. I am open to suggestions and ideas. If you know a better setup then just post it in the comments. 😊
I'm still relatively at the beginning so please be forgiving 😅.
Investment decisions during the crash
Hello everyone,
Things have been a bit quiet for me over the last few months.
Here are a few investments that I made during this period and also during the crash.
Buy:
Tranche: Entry at €57.90
Tranche: € 64.60
Entry at € 205.25
Entry at € 108.32
Entry at € 140.40
Further tranche at € 3.26
Sell:
Sell at 426€
Sale at 40,99€
During this time, I also $RHM (-0.23%) and $TSLA (+3.23%) shorted, losing 100% on the respective shorts :D.
What investments did you make during this time?
Rumors Novo Nordisk - Patent not paid
I have found the following:
Yesterday rumors surfaced that $NOVO B (+2.06%) had not paid the maintenance fee for its semaglutide patent in Canada, causing the patent to expire prematurely. This could pave the way for generic competition in Canada as early as 2026, years before the patent expires in other countries.
The article that first reported this was published six days ago. So far, no market reaction. Novo has not commented. It remains unconfirmed.
At first glance, it seems unlikely that Novo simply "forgot" to pay, but some have suggested that it may have been a deliberate strategy related to Canada's unique pricing rules.
In Canada, patented drugs are under the jurisdiction of the PMPRB, a pricing authority that limits the prices of patented drugs. However, if a drug is not patented, the PMPRB loses jurisdiction. So no patent means no price control (until generics come on the market).
When the patent expired, the PMPRB proposed stricter price regulations that could have led to a significant price reduction for drugs like Ozempic.
Novo may have compromised:
- Lose patent protection sooner
- In the meantime, avoid PMPRB price controls
- Maximize pricing while still enjoying de facto exclusivity (until generics come to market).
Interestingly, other Canadian patent applications for Ozempic have also been withdrawn, suggesting that this may not have been a one-off mistake but a deliberate IP strategy.
In a nutshell:
It may not be a case of incompetence/a mistake , but a choice between longer exclusivity under price caps and shorter exclusivity with freer pricing.
However, these are unconfirmed rumors and not official statements.
Here is also a report on this:
https://www.labiotech.eu/in-depth/novo-nordisk-semaglutide-patent-expiration-canada/
https://www.ncbi.nlm.nih.gov/books/NBK602920/table/t03/
Let's see how it goes on ✌️
Novo Nordisk vergisst Patentverlängerung in Kanada 🤣
Novo Nordisk hat vergessen, das Patent für Semaglutid in Kanada zu erneuern, was bedeutet, dass das generische Ozempic im Jahr 2026 verfügbar sein wird.
Novo Nordisk hat das Patent für Semaglutid, den Wirkstoff von Ozempic, in Kanada aufgrund einer ausstehenden Gebühr von 450 US-Dollar nicht verlängert. Dies ermöglicht den Verkauf von Generika ab 2026 und dürfte die Kosten für Patienten mit Diabetes oder Übergewicht senken. Dies könnte zwar den Zugang verbessern, aber den Umsatz von Novo Nordisk verringern.
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
Saynor: Canada, we filed and are waiting for approval once the data exclusivity expires sometime in Q1 next year. Interesting market. Novo never filed a patent in Canada. Never know why. I’m sure someone’s lost their job, but never mind. It’s the second-largest semaglutide market in the world. 😂
This change is specific to Canada for now—patents for semaglutide in the US and Europe last until the early 2030s, so generics won’t show up there for several more years.
Novo Nordisk's annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.
"For Ozempic in Canada, regulatory data protection applies until 2026," says the report from Novo Nordisk (DK:NOVO.B) (NVO), which last week reclaimed the mantle of being Europe's largest company by market capitalization.
Why that's the case was brought to light in a column in the publication Science, which picked up on an interview with the head of generics drug maker Sandoz (CH:SDZ), which has filed to make a generic version. (Hikma Pharmaceuticals (UK:HIK) and Aspen Pharmaceuticals (ZA:APN) are also doing so.)
The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks.
In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual $250 maintenance fee on time, but the company could maintain the patent by paying a total of $450.
"Once a patent has lapsed, it cannot be revived," the letter on May 1, 2019, warned. And that was the last of the correspondence on the Canadian patent for semaglutide, the medication in Ozempic.
How much of a loss is that? The Globe and Mail, citing data from Iqvia, said total sales of Ozempic were $2.5 billion through retail pharmacies last year, making it the number-one drug in Canada.
The real interesting footnote to the footnote comes in a discussion on whether a Canadian Ozempic generic could qualify for U.S. use under what's called the Section 804 importation program. Florida so far is the only state that so far has dialogue with the Food and Drug Administration about launching such a program.


Novo Nordisk vergisst Patentverlängerung in Kanada 🤣
Novo Nordisk hat vergessen, das Patent für Semaglutid in Kanada zu erneuern, was bedeutet, dass das generische Ozempic im Jahr 2026 verfügbar sein wird.
Novo Nordisk hat das Patent für Semaglutid, den Wirkstoff von Ozempic, in Kanada aufgrund einer ausstehenden Gebühr von 450 US-Dollar nicht verlängert. Dies ermöglicht den Verkauf von Generika ab 2026 und dürfte die Kosten für Patienten mit Diabetes oder Übergewicht senken. Dies könnte zwar den Zugang verbessern, aber den Umsatz von Novo Nordisk verringern.
https://www.science.org/content/blog-post/novo-nordisk-s-canadian-mistake
Saynor: Canada, we filed and are waiting for approval once the data exclusivity expires sometime in Q1 next year. Interesting market. Novo never filed a patent in Canada. Never know why. I’m sure someone’s lost their job, but never mind. It’s the second-largest semaglutide market in the world. 😂
This change is specific to Canada for now—patents for semaglutide in the US and Europe last until the early 2030s, so generics won’t show up there for several more years.
Novo Nordisk's annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.
"For Ozempic in Canada, regulatory data protection applies until 2026," says the report from Novo Nordisk (DK:NOVO.B) (NVO), which last week reclaimed the mantle of being Europe's largest company by market capitalization.
Why that's the case was brought to light in a column in the publication Science, which picked up on an interview with the head of generics drug maker Sandoz (CH:SDZ), which has filed to make a generic version. (Hikma Pharmaceuticals (UK:HIK) and Aspen Pharmaceuticals (ZA:APN) are also doing so.)
The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks.
In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual $250 maintenance fee on time, but the company could maintain the patent by paying a total of $450.
"Once a patent has lapsed, it cannot be revived," the letter on May 1, 2019, warned. And that was the last of the correspondence on the Canadian patent for semaglutide, the medication in Ozempic.
How much of a loss is that? The Globe and Mail, citing data from Iqvia, said total sales of Ozempic were $2.5 billion through retail pharmacies last year, making it the number-one drug in Canada.
The real interesting footnote to the footnote comes in a discussion on whether a Canadian Ozempic generic could qualify for U.S. use under what's called the Section 804 importation program. Florida so far is the only state that so far has dialogue with the Food and Drug Administration about launching such a program.


In any case, it is embarrassing.
NOVO NORDISK
Hello guys, what's the difference between $NVO (+1.85%) (ADR) and $NOVO B (+2.06%) (B) ?
Thanks in advance.
Lilly Q1 Earnings Highlights
$LLY (+1.32%)
$HIMS (+0.1%)
$NOVO B (+2.06%)
$NVO (+1.85%)
- Revenue: $12.73B (est. $12.72B) ✅; +45%
- Adj. EPS: $3.34 (est. $3.46) ❌; +29% YoY
- Net Income (Adj): $3.00B (est. $2.72B) ✅
FY25 Guide"
- Adj. EPS: $20.78–$22.28 (Prior: $22.50–$24.00)
- Revenue: $58B–$61B (est. $59.57B)
- Performance Margin: 41.5%–43.5% (Adj)
- Effective Tax Rate: ~17% (Prior: ~16%)
- Other Expense (Reported): ($850M)–($750M)
- Capex/Manufacturing: Expanded; 4 new facilities announced
- Guidance Based On Existing Tariff, Environment
Key Product Revenue (Q1 YoY)
- Mounjaro: $3.84B (+113%)
- Zepbound: $2.31B (Est. $2.3B)
- Verzenio: $1.16B (+10%)
- U.S. Revenue: $8.49B (+49%)
- Intl Revenue: $4.24B (+38%)
Other Key Metrics:
- Gross Margin: 83.5% (Adj); +100 bps
- R&D Expenses: $2.73B (+8%); 21.5% of revenue
- SG&A: $2.47B (+26%)
- Acquired IPR&D: $1.57B (or $1.72/share)
Pipeline Progress:
• Orforglipron (oral GLP-1) Phase 3 success
• Donanemab awaiting CHMP outcome
• Jaypirca approved in EU for R/R CLL
• Lepodisiran shows 94% Lp(a) reduction
• Baricitinib shows positive adolescent AA results
• EBGLYSS: 50% clear skin at 3 years
• Omvoh: sustained remission in Crohn’s
Business Developments:
- Expanded Zepbound vial offerings + savings for self-pay
- LillyDirect expands Alzheimer’s access
- >$50B U.S. manufacturing investment (since 2020)
CEO David Ricks Commentary
- “We had a solid start to the year with 45% revenue growth led by Mounjaro and Zepbound. Our pipeline continues to deliver, and we are scaling manufacturing to meet growing global demand.”

Podcast episode 86 "Buy High. Sell Low."
Podcast episode 86 "Buy High. Sell Low."
Subscribe to the podcast so that the Robotaxis come soon.
00:00:00 Tesla
00:34:00 Alphabet
01:07:41 Outlook & FED
01:30:28 Eli Lilly & Novo Nordisk
Spotify
https://open.spotify.com/episode/3T1lQR57YSbyUAbnmnSFoz?si=DHM2pXoOSkSCfy2CAC2q-Q
YouTube
https://www.youtube.com/watch?v=n8Wcn4sUuqM
Apple Podcast
$TSLA (+3.23%)
$GOOG (+0.4%)
$GOOGL (+0.4%)
$LLY (+1.32%)
$NVO (+1.85%)
$SPOT (-0.62%)
$AAPL (+1.05%)
Trending Securities
Top creators this week